Notably, in systemic sclerosis (SSc), TGF-β drives fibroblast transition via Smad signaling (79), whereas baricitinib’s EGFR affinity downregulates COL1A1/COL3A1 to restore collagen density in skin models (80). Here, TGFB1 is linked to systemic sclerosis.